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HUH and McCarter (1960) showed that under certaiii conditions phenanthrene
inhibited tumour initiation by 9,10-dimethyl-1,2-benzanthracene (DMBA).
Since then Bock and Burnham (1961) have reported that the presence of phenan-
threne in a solution of benzopyrene (BP) in benzene and mineral oil (1 per cent)
reduced the concentration of the carcinogen present in the skin 2 hours after
application, as compared with skin treated with the solvent and BP alone. In
the light of these reports Roe (1962) attempted to inhibit the tumour initiating
effect of a single dose of BP by prior and post administration (either by applica-
tion to the skin or by subcutaneous injection) of phenanthrene. No inhibition
was observed. The experiment described in the present paper was designed to
test phenanthrene for anticarcinogenic activity under quite different conditions.
Since the paper of Pietra, Spencer and Shubik (1959) it has become
increasingly clear that cancer of various sites can be induced by the injection of
quite small doses of carcinogens into newly born mice. The same group of
workers (Pietra et al., 1961) and others (Roe, Rowson and Salaman, 1961;
Fiore-Donati et al., 1961; Stich, 1960; Kelly and O'Gara, 1961) confirmed
and extended the original observation; and Roe et al. (1961) suggested that new-
born mice might be used to screen substances for carcinogenic activity. In the
experiment described below newly born mice are used to test the ability of
phenanthrene to inhibit or enhance carcinogenesis by BP.
MATERIALS AND METHODS
Mice.-The litters used came from stock albino mice obtained originally from
Messrs. Schofield, Intake Head, Delph, near Oldham, Lancs. They were housed
in metal cages and fed on diet 41B and water, both given ad libiturm.
Chemical agents.-3,4-Benzopyrene (BP) was obtained from L. Light and
Co. and phenanthrene from a sample of high purity prepared in the Institute.
Acetone (Analar grade) and gelatin powder were obtained from British Drug
Houses Ltd.
For the purpose ofinjection, suspensions of BP and phenanthrene in 1 per cent
aqueous gelatin were prepared by adding acetone solutions of the hydrocarbons
to the gelatin solution at 5600. and subsequently removing the acetone in a stream
of nitrogen.G. GRANT AND F. J. C. ROE
EXPERIMENTAL
Sixty pregnant females were allotted randomly to seven experimental groups.
Within 24 hours of birth the young mice were injected subcutaneously with test
or control materials. All the mice in a single litter were placed in the same group.
Details of treatment are shown in Table I. The injection was given so that a
" blister " of the injected material could be seen in the subcutaneous tissues of
the neck posterior to one ear, whilst the point where the needle penetrated the
skin was close to the root of the tail (i.e. as remote as possible from the point of
delivery ofthe injected material). Where both BP and phenanthrene were given,
they were injected consecutively in time, one substance to the right side and the
other to the left side of the neck.
Mice which died during the first 10 weeks of the experiment were disregarded.
All mice which died subsequently were carefully examined post mortem fortumours
of all sites. Ten mice from each group were killed at 52 weeks and the remainder
at 62 weeks. The post-mortem and histological findings are recorded in Tables
I and II.
TABLE I.-Incidence of Pulmonary Adenomas
Mice with
adenomas
Treatment Number of Survivors Average number
[ag = 1% mice alive for 50 Percentage of adenomas
Group aqueous gelatin] at 10 weeks or more weeks* of group per survivor
1 0-02 ml. ag 45 8/34 24 0o3
2 0 04ml. ag 45 5/38 13 0.2
3 20,ug. BP in 0-02 ml. ag 48 9/35 26 0-3
{204pg. BP in 0-02 ml. ag
20 ,pg. Phenanthrene 60 10/42 2 03
in 0-02 ml. ag
B 40pg. BP in 0-02 ml. ag 51 20/45 44 0-8
r40pg. BP in 0-02 ml. ag
6 40+g 631±34
-
40 ug. Phenanthrene 63 18/43 42 0 7
Uin 002 ml. ag
7 40,ug. Phenanthrene 57 3/49 6 0-1
in 0-02 ml. ag
* 10 mice of each group were killed at 52 weeks and the survivors of each group were killed at 62
weeks.
The commonest tumour in all groups was the lung adenoma. This was found
in 24and 13per cent, respectively, ofthe mice ofthetwo controlgroupstreated with
aqueousgelatin only (Groups 1 and 2). Inthe groupstreated withBP(Groups 3,4,5,
and 6) the percentage of mice developing lung adenomas and the averagenumber
of these tumours per survivor were higher than in the controls. The difference
between Groups 5 and 6, on the one hand and Groups 1 and 2 on the other was
significant (X2 - 11-53, P<0*001). The incidence in Groups 3 and 4 was inter-
mediate and was not significantly different from the controls. Phenanthrene
appeared to have no effect on the induction of pulmonary tumours by either
20 ,ug. BP or 40 ,ug. BP; nor did it induce lung tumours when administered
without BP treatment. The commonest tumours other than pulmonary adeno-
mas were lymphocytic neoplasms, parenchymal-cell hepatomas and mammary
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adenocarcinomas (Table II). Only one mouse in the two control groups developed
a lymphocytic neoplasm; this appeared relatively late in life and was discovered
at post mortem. Some mice from each BP treated group died from this cause be-
tween 20 and 52 weeks ofage and others werefound to have ageneralised lymphocy-
tic neoplasm when killed at 52 to 62 weeks. Among the BP-inducedlymphocytic
neoplasms, two of " stem cell " type were recorded, one in a mouse ofGroup 4 and
the other in a mouse of Group 5; these died at 15 and 30 weeks respectively.
A mouse in Group 5 was found to have myeloid leukaemia when killed at the
termination of the experiment. Hepatomas and mammary adenocarcinomas
were found in some mice of all groups. The incidence of both was apparently
increased by BP and this increase was unaffected by the administration of
phenanthrene.
DISCUSSION
Taken together the results indicate quite decisively that phenanthrene does
not affect the induction of tumours by BP under the experimental conditions
described.
Compared with 9,10-dimethyl-1,2-benzanthracene (DMBA) BP had only a
feeble carcinogenic effect when administered to newly born mice ; a 30 ag. dose
ofDMBA gave rise to an average of 13 lung adenomas in mice of 2 different strains
killed at 52 weeks (see Roe et al., 1961) whereas in the present experimenit 40 ,ug.
BP gave rise to an average of less than one adenoma per survivor. Nevertheless
sufficient pulmonary tumours were induced in the present experiment to enable
one to be confident that phenanthrene in the doses given was without effect on
tumour yield. Similarly BP was much less productive of malignant lymphomas
ofstem cell type than DMBA only 2 being recorded in 222 BP-treated mice whereas
in the case ofDMBA there was an incidence ofbetween 15 and 20 per cent between
the 10th and 33rd week, depending on the strain. A surprising finding and one
which requires confirmation, was the raised incidence ofhepatomas in mice treated
with BP. Hartwell (1951) and Shubik and Hartwell (1957) record no experiments
in which benzopyrene increased the incidence of liver tumours. Even when BP
was injected directly into the liver of rats parenchymal cell tumours were nlot
induced (Oberling, Guerin and Guerin, 1939).
The experiment differed from that carried out by Huh and McCarter (1960)
in that BP and the phenanthrene were introduced subcutaneously so that there
was no scope for phenanthrene to modify carcinogenesis by BP by interfering
with the absorption of the latter into the tissues. The failure to observe any
inhibition of the carcinogenicity of BP by phenanthrene is in agreement with the
results published by Roe (1962). In the present experiment however there was
no real evidence that phenanthrene increased the activity of BP.
SUMMARY
Groups of newly born mice, less than 24 hours old, were given suspensions of
the following in 1 per cent aqueous gelatin :- 20 jug. 3,4-benzopyrene (BP);
20 ,ug. BP + 20 ,ug. phenanthrene; 40 ,ug. BP; 40 ,ug. BP + 40 ,ug. phenan-
threne; or 40 ,ug. phenanthrene, and then kept for 52 or 62 weeks before they
were killed. In addition two groups were observed following injection of aqueous
gelatin only.
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The incidence of pulmonary adenomas and of other tumours (lymphomas,
hepatomas and mammary adenocarcinomas) seen in response to treatment with
BP was not increased or reduced by the administration of phenanthrene.
The incidence of tumours in the group which received phenanthrene only was
no higher than that seen in the two solvent-only control groups.
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